Facebook
Twitter
Telegram
Report an ErrorAcasti Pharma Balance Sheet 2011-2024 | ACST
Annual Balance Sheet Acasti Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-27.4 M | -30 M | - | - | -15.5 M | -5.12 M | - | -2.23 M | -1.05 M | -607 K | -1.17 M | -1.6 M | -329 K |
Long Term Debt |
410 K | 191 K | - | - | - | 1.25 M | - | - | - | - | - | - | - |
Long Term Debt Current |
75 K | 104 K | 86 K | 76 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 12.2 M | 6.22 M | - | 115 K | 1.88 M | 10 M | - | - | 4.27 M |
Total Current Liabilities |
3.41 M | 3.26 M | 1.58 M | 7.4 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
11.2 M | 20.4 M | 6.8 M | - | 25.8 M | 11.4 M | - | 957 K | 3.18 M | 11.1 M | 2.39 M | 1.27 M | 5.24 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-198 M | -156 M | -146 M | - | -92.8 M | -56 M | - | -29.2 M | -26.6 M | -28.5 M | -19.6 M | -13.2 M | -14.3 M |
Total Assets |
79.1 M | 129 M | 62.5 M | 14 K | 36.3 M | 17.8 M | - | 21 M | 29.7 M | 41 M | 11.9 M | 15.8 M | 3.4 M |
Cash and Cash Equivalents |
27.9 M | 30.3 M | 50.9 M | 14.2 M | - | - | - | - | - | - | - | - | - |
Book Value |
68 M | 108 M | 55.7 M | 14 K | 10.5 M | 6.37 M | - | 20.1 M | 26.6 M | 29.9 M | 9.5 M | 14.6 M | -1.84 M |
Total Shareholders Equity |
68 M | 108 M | 55.7 M | 13 M | 11 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Acasti Pharma
| 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 410 K | 430 K | 450 K | 174 K | 191 K | - | - | - | - | - | 38 K | 56 K | 71 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
11.5 M | 11.5 M | 9.02 M | 11.2 M | 20.1 M | 20.7 M | 20.5 M | 20.4 M | 3.16 M | 5.59 M | 7 M | 6.8 M | 4.59 M | 4.96 M | 9.11 M | 9.86 M | - | - | - | 25.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-208 M | -206 M | -202 M | -198 M | -169 M | -165 M | -160 M | -156 M | -152 M | -148 M | -149 M | -146 M | -140 M | -137 M | -131 M | -126 M | - | - | - | -101 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
76.2 M | 78.2 M | 73 M | 79.1 M | 117 M | 121 M | 125 M | 129 M | 114 M | 120 M | 60.5 M | 62.5 M | 30.3 M | 13.8 M | 20.1 M | 22.9 M | - | - | - | 36.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
18.5 M | 27 M | 21.6 M | 27.9 M | 26.2 M | 34.9 M | 38.4 M | 30.3 M | 33 M | 36.9 M | 41 M | 50.9 M | 26.5 M | 11.6 M | 12.1 M | 14.2 M | 16.9 M | 2.62 M | 1.11 M | 16.9 M | 6.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
64.7 M | 66.7 M | 64 M | 68 M | 96.7 M | 100 M | 104 M | 108 M | 111 M | 114 M | 53.5 M | 55.7 M | 25.7 M | 8.87 M | 11 M | 13 M | - | - | - | 11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
64.7 M | 66.7 M | 64 M | 68 M | 96.7 M | 100 M | 104 M | 108 M | 111 M | 114 M | 53.5 M | 55.7 M | 25.7 M | 25.7 M | 8.87 M | 11 M | -4.29 M | -759 K | 3.28 M | 11 M | - | - | - | 7.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency